rb 6145 has been researched along with vadimezan in 1 studies
| Studies (rb 6145) | Trials (rb 6145) | Recent Studies (post-2010) (rb 6145) | Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) |
|---|---|---|---|---|---|
| 38 | 0 | 2 | 272 | 16 | 101 |
| Protein | Taxonomy | rb 6145 (IC50) | vadimezan (IC50) |
|---|---|---|---|
| Stimulator of interferon genes protein | Mus musculus (house mouse) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baguley, BC; Lash, CJ; Li, AE; Rutland, M; Wilson, WR; Zwi, LJ | 1 |
1 other study(ies) available for rb 6145 and vadimezan
| Article | Year |
|---|---|
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Mice; Mice, Inbred C3H; Nitrogen Mustard Compounds; Nitroimidazoles; Prodrugs; Regional Blood Flow; Serotonin; Tirapazamine; Triazines; Xanthenes; Xanthones | 1998 |